Lourdes Riquelme, Author at Labiotech.eu

About

Spanish Biotechnologist with a MS in Genetics from Universidad Autonoma of Barcelona. My interests go from science to fashion and anything in between.

Articles by Lourdes Riquelme

News and Trends 15 Jun 2015

GSK’s undercover incubator baked three new Biotechs

The partnership between GlaxoSmithKline and Avalon Ventures launched three early-stage life science companies. Adrenergics, CadheRx Therapeutics and Calporta Therapeutics will each receive up to €8.9M in a Series A financing, aside from support from their two godfathers. Three new companies were launched today as a result of Avalon’s fruitful collaboration with GSK. The partnership, which […]

June 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Jun 2015

Jonhson&Jonhson hurries up Genmab’s myeloma treatment

Genmab and its partner Jonhson&Jonhson, through its subsidiary Janssen Biotech, are trying to speed up daratumumab. The companies initiated a rolling submission for the candidate that targets multiple myeloma. The German-American partnership is trying to accelerate the arrival of daratumumab to the market, only just after the presentation of optimistic results of MOR202’s phase I/IIa. […]

June 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 12 Jun 2015

The first-in-human proof that Epigenetics marks are transmitted to the offspring

If a father works out every night and day at the gym, will he have a brawny baby? Well, yes and no. It might sound Lamarckian but the French naturalist might have had a point. A team of researchers from the University of Cambridge has described for the first time in humans how some regions […]

June 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 12 Jun 2015

MRC Technology and Peptinnovate partnered to cure bone diseases

MRC Technology and Peptinnovate teamed up to target bone diseases using peptides derived from the bacterium Mycobacterium tuberculosis. The partnership was created at Stevenage Bioscience Catalyst, a UK-based life sciences cluster. Natural peptides from M. tuberculosis, the pathogen that causes this feared disease, are able to modify the immunological and inflammatory response in humans. The bacteria employ […]

June 12, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 12 Jun 2015

Polaris, a new Nordic leader in Immuno-Oncology

Immuno-oncology is a busy market to take on by yourself due to the existing fierce competition. Targovax and Oncos Therapeutics have decided to merge to earn a spot in the field. Polaris, the combined business, contemplates a private placement of around €15M to fund the freshly baked company. Finland and Norway never were this close as Oncos […]

June 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 Jun 2015

Cosmo’s dermatology spin-out Cassiopea IPOes before the end of its Phase III

Cassiopea, Cosmo Pharmaceutical’s spin-out, will be listed on the Swiss Stock Exchange. Cosmo Pharmaceutical plans to reduce its current 97% shareholding to below the 50% bar. The majority shareholder will give away the control of its subsidiary in order to have enough cash after the end of its Phase III ACNE-treatment, currently running in the US and […]

June 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 Jun 2015

Pieris Pharma: is it worth going to NASDAQ for only €31 Million?

Pieris Pharmaceutical is planning to raise €31M in an surprisingly low US IPO. The company seeks to advance its early-stage pipeline with a special focus on its anemia treatment, Pieris’s most advanced candidate which recently completed the enrollment of its Phase I. Pieris’ pipeline might be premature, but it is ambitious. The company’s focus includes […]

June 11, 2015 - 2 minutesmins - By Lourdes Riquelme

diabetes type 2 sanofi novo nordisk eli lilly

News and Trends 11 Jun 2015

Pharmas step on the gas chasing the next blockbuster in Type 2 Diabetes

Hundreds of millions of people all over the word suffer from type 2 Diabetes and the competition between pharma companies is fierce. Amongst them, Sanofi must think that good things come to those who wait. After years of delay, the French colossus is convinced with the Phase IIIb results on its type 2 diabetes treatment. […]

June 11, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 10 Jun 2015

French collaboration to develop Oncology-targeted Therapy

PEP-Therapy and CleveXel Pharma will co-develop targeted therapy in oncology. The product is based on an innovative technology involving bi-functional peptides that penetrate cells, and specifically block pathological mechanisms without affecting physiological mechanisms. The drug candidate is a cell-penetrating peptide that targets an interaction between two intracellular proteins, Caspase-9 and PP2A. It has been validated […]

June 10, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 9 Jun 2015

Novozymes to construct a new R&D campus in Denmark

Novozymes will build a new campus dedicated to research and business development in Denmark, in the north of Copenhagen. With 140,000 square meters, the company expects that the new innovation campus will be a cornerstone for Novozymes’ global research. The location, in close proximity to the Technical University of Denmark aims at creating a global […]

June 9, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 9 Jun 2015

Apitope’s peptide to take on Haemophilia A

Apitope’s pre-clinical candidate ATX-F8-117 has been granted Orphan Drug Status by the US FDA for the treatment of Haemophilia A. The drug candidate already obtained an Orphan Drug Designation by the European Medical Agency last year. The compound also awakened the interest of Abzena, which works with Apitope to design the candidate. Haemophilia A is […]

June 9, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 8 Jun 2015

Biosimilars will land in Poland thanks to a European loan

Biosimilars will have their Polish guarantor. Polpharma, the largest Polish producer of medicines, is the first benefactor of a €45M loan granted by the European Investment Bank. The loan was granted for research and development of biosimilars and is part of InnovFin, the EU fund for innovators. The production of biosimilars involves numerous difficulties in […]

June 8, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Lourdes Riquelme

About

Articles by Lourdes Riquelme

GSK’s undercover incubator baked three new Biotechs

Jonhson&Jonhson hurries up Genmab’s myeloma treatment

The first-in-human proof that Epigenetics marks are transmitted to the offspring

MRC Technology and Peptinnovate partnered to cure bone diseases

Polaris, a new Nordic leader in Immuno-Oncology

Cosmo’s dermatology spin-out Cassiopea IPOes before the end of its Phase III

Pieris Pharma: is it worth going to NASDAQ for only €31 Million?

Pharmas step on the gas chasing the next blockbuster in Type 2 Diabetes

French collaboration to develop Oncology-targeted Therapy

Novozymes to construct a new R&D campus in Denmark

Apitope’s peptide to take on Haemophilia A

Biosimilars will land in Poland thanks to a European loan

Subscribe to our newsletter to get the latest biotech news!